Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for ...

Nearly half of women diagnosed with ovarian cancer are not receiving the genetic testing that could help guide treatment and improve outcomes, according to a new analysis from Ovarian Cancer Research ...

OpEd: I was diagnosed with colon cancer at 34. An early screening could have saved my life – and there are thousands of ...

Current law mandates patients with metastatic breast cancer must wait five months before earning any SSDI benefits.

Terminal cancer.” At only 34 years old, that was the last diagnosis I expected to hear from my doctor. For years, the mild ...

Guardant Health’s co-CEO, AmirAli Talasaz, expressed pride in the potential lifesaving impact of the Shield blood test for veterans and their families. This coverage decision by the VA represents a ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...

(Note: Toni has had a death in her family, so we are sending this column from August of 2023. It has been revised and updated ...

Under new federal rules, doctors and imaging centers have to more closely track and report the doses of radiation that ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.

The bill is an attempt to eliminate the waiting period for Social Security and Medicare coverage for patients with metastatic breast cancer. Roughly 170,000 Americans are living with metastatic ...

Researchers warn that radiation from the machines can increase cancer risk. New Medicare rules aim to make these imaging ...